# KMC Speciality Hospitals (India) share price today (KMC Speciality Hospitals (India) Ltd, NSE: KMCSHIL) > KMC Speciality Hospitals (India) share price today: ₹197.42 at the NSE close on 18 November 2026, up 154.7% in a year. KMC Speciality Hospitals (India) (NSE: KMCSHIL) is worth ₹3,217 crore, trades at a P/E of 52.6 and has closed between ₹74.85 and ₹197.42 over the past 52 weeks. > KMC Speciality Hospitals (India) Ltd's share price has risen faster than its earnings: +154.7% in a year, against +119.1% for earnings per share. KMCSHIL · Hospitals · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Getting better, from the last 12 quarters - Price: ₹197.42 (+154.7% in a year) - P/E: 52.6× (higher than 87% of the last 11 years) - Revenue (Sep 2026): ₹93.0 Cr (+24.0% on a year ago) - Profit (Sep 2026): ₹16.0 Cr (+45.5% on a year ago) - Operating margin: 30.1% (+2.1 points on a year ago) - ROCE: 26%, FY26 - ROIC: 24.2%, against a 12.0% cost of capital: +12.2 points The main question: the share price moved +154.7% in a year while yearly earnings per share moved +119.1%. The difference came from the market paying a higher multiple. ## What is the KMC Speciality Hospitals (India) share price today? KMC Speciality Hospitals (India) Ltd's share price was ₹197.42 at the close on 18 November 2026. It has been rising for 52 weeks. That is 58.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹75 and ₹197, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 44 weeks in a row. Over the last 11 years the share price moved +2,276% while the NIFTY 500 moved +279%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at KMC Speciality Hospitals (India) this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), profit up on a year earlier for 6 quarters in a row and highest quarterly revenue in 16 quarters. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹93 crore, +24% on a year earlier. 2. Profit up on a year earlier for 6 quarters in a row In the September 2026 quarter profit was ₹16 crore, +45.5% on a year earlier. 3. Highest quarterly revenue in 16 quarters Revenue of ₹93 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are KMC Speciality Hospitals (India)'s latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), KMC Speciality Hospitals (India) reported revenue of ₹93.0 crore, up 24.0% from ₹75.0 crore a year earlier, and a profit of ₹16.0 crore, up 45.5% from ₹11.0 crore. ### KMC Speciality Hospitals (India) results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹93.0 crore | ₹75.0 crore | +24.0% | | Profit | ₹16.0 crore | ₹11.0 crore | +45.5% | | Earnings per share | ₹0.99 | ₹0.66 | +50.0% | | Operating margin | 30.1% | 28.0% | +2.1 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the KMC Speciality Hospitals (India) share price history? KMC Speciality Hospitals (India) closed at ₹197.42 on 18 November 2026, up 154.7% from ₹77.51 a year earlier (21 November 2025) and up 208.0% over five years. Its highest weekly close since March 2016 was ₹197.42 on 18 November 2026. ### KMC Speciality Hospitals (India) share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹168.94 | +16.9% | | 1 month ago · 19 Oct 2026 | ₹156.98 | +25.8% | | 1 year ago · 21 Nov 2025 | ₹77.51 | +154.7% | | 3 years ago · 17 Nov 2023 | ₹82.23 | +140.1% | | 5 years ago · 18 Nov 2021 | ₹64.10 | +208.0% | | 10 years ago · 18 Nov 2016 | ₹9.55 | +1,967.2% | | Earliest weekly close in our records · 11 Mar 2016 | ₹8.31 | +2,275.7% | | Highest weekly close since March 2016, also the 52-week high · 18 Nov 2026 | ₹197.42 | 0.0% | | Lowest weekly close since March 2016 · 8 Apr 2016 | ₹7.07 | +2,692.4% | | 52-week low (weekly close) · 1 Feb 2026 | ₹74.85 | +163.8% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (542 weekly closes from 11 March 2016 to 18 November 2026.) ## What is the latest news on KMC Speciality Hospitals (India)? 18 Nov 2026: KMC Speciality Hospitals (India) closed at ₹197.42, up 16.9% on the week and up 25.8% on the month. Results for July to September 2026: Revenue up 24.0% and profit up 45.5% on a year earlier. ## What dividend does KMC Speciality Hospitals (India) pay? KMC Speciality Hospitals (India) has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. KMC Speciality Hospitals (India) Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 18 November 2026.) ## What to watch in KMC Speciality Hospitals (India)'s next results? When KMC Speciality Hospitals (India) reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +24.0% on a year earlier, and the last four quarters averaged +32.5%. - Whether the operating margin stays near 30.1%. The latest full year's operating margin was the highest on file. Every ratio built on profit looks better at a peak. - Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +45.5% on a year earlier. It has grown on a year earlier for 6 quarters in a row. ## Which stock lists is KMC Speciality Hospitals (India) on? KMC Speciality Hospitals (India) is on one of our India lists: Momentum stocks. [Momentum stocks Market value: ₹3,172 crore](https://www.sectoralpha.in/momentum-stocks-india) ## Is KMC Speciality Hospitals (India) profitable? KMC Speciality Hospitals (India) Ltd earned ₹16.0 Cr of net profit in the Sep 2026 quarter, +45.5% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY26 profit was ₹47.0 Cr. Over 10 years profit has grown 31.7% a year on average. The Sep 2026 quarter's profit is 17.2% of that quarter's revenue. The same quarter a year earlier earned ₹11.0 Cr. For the full year, FY26 profit was ₹47.0 Cr (+123.8% on the year before). Why profit moved: revenue changed +24.0% on a year earlier and the margin moved +2.1 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +108.3% and revenue +32.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does KMC Speciality Hospitals (India) make, and is it growing? KMC Speciality Hospitals (India) Ltd reported ₹93.0 Cr of revenue in the Sep 2026 quarter, +24.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 21.7% a year on average. The last full year, FY26, came in at ₹306 Cr. Why this happened. OPD is the top-of-funnel for IPD conversion. 92% of inpatients come from nine districts around Trichy. OPD growth at 32% YoY indicates brand penetration is still expanding in the catchment, not yet saturated. Tele-medicine implementation (per FY25 annual report) is extending reach into rural areas beyond physical travel distance. The last four reported quarters add to ₹349 Cr. FY26 revenue was ₹306 Cr, +31.9% on the year before. Recent pace: the last four quarters grew +32.5% on average, against 21.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +32.2%, against +31.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +93.8%, against +54.4% a year (accelerating). ## How much of every ₹100 of sales does KMC Speciality Hospitals (India) keep? KMC Speciality Hospitals (India) Ltd's operating margin was 30.1% in the Sep 2026 quarter, 2.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 6.3% and 28.8%. The latest quarter is above every full year in that period. Why this happened. The dominant driver. The Maa Kauvery facility added 200 beds to the existing 250-bed campus, bringing total capacity to 450 beds. Census beds (occupied) are 330, reflecting that Maa Kauvery is still ramping toward census capacity. As this facility fills up, every incremental rupee of revenue has very high flow-through to EBITDA because doctors, nursing staff, facility costs are largely sunk. Q3 FY26 illustrates this: expenses up 23.2% on revenue up 33.7%. EBITDA margin expanded from 27.5% to 31.1%. Why the margin moved: operating margin changed +2.6 percentage points on the year while gross margin changed −0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is KMC Speciality Hospitals (India)'s profit turning into cash? Over the last 3 years, 179% of KMC Speciality Hospitals (India) Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹79.0 Cr of operating cash against ₹47.0 Cr of profit. After ₹17.0 Cr of spending on assets, ₹62.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 179% of profit came in as cash: the cash cycle got 26 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.1× depreciation over three years. The next section checks what that spending is building. ## Where does KMC Speciality Hospitals (India)'s cash go? KMC Speciality Hospitals (India) Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −42 days in FY26, up from −68 days in FY21. It spent ₹156 Cr on assets over the last 3 years. Customers take 9 days to pay, and stock sits for 31 days on average. At FY26 sales of ₹306 Cr, each day of that cycle ties up about ₹0.8 Cr, so roughly −₹35.0 Cr is tied up in the business at any time. FY26: customers took 9 days to pay and stock sat for 31 days, about 1.0 months of sales sitting as stock, for a full cycle of −42 days, longer than FY21's −68. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 31 days. Customers pay about 9 days after that. Suppliers are paid at 82 days. Together that makes the −42-day cycle. Spending on assets: ₹156 Cr over the last 3 years, against ₹50.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is KMC Speciality Hospitals (India)'s P/E ratio, and how does it compare with its own history? KMC Speciality Hospitals (India) Ltd's P/E is 52.6×, near the high end of its own history: higher than 87% of past readings. Its usual P/E (the middle reading) is 43.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +119.1% while the price moved +154.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +25.2% a year; about +27.8% a year came from earnings growth and about −2.6 percentage points from the multiple (the market paying less); over 10 years the price moved +35.4% a year; about +33.4% a year came from earnings growth and about +2.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the KMC Speciality Hospitals (India) business getting better or worse? KMC Speciality Hospitals (India) Ltd's business is getting better. Profit growth was −16.7% 6 quarters ago and has recovered to +93.8%, with ROCE rising at 30.9% (four quarters to Jun 2026). This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## What is the KMC Speciality Hospitals (India) story, and has it been checked? KMC Speciality Hospitals (India) Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: mid expansion. Still open: One hospital, one city, any adverse event (key doctor attrition, clinical incident, regulatory action) has no operational hedge. Our read, 17 May 2026. Maa Kauvery ramp-up is still printing: occupancy at 82%, ARPOB +17% YoY, operating leverage is working and the gestation drag is behind us. From the numbers. EPS trajectory is upward: ₹0.28 → ₹0.46 → ₹0.66 → ₹0.84 in last 4 quarters. TTM PAT YoY +52% confirms EARNINGS DRIVEN cycle. From the price. Price stage 2, week 52, above its 200-day line, relative strength falling. Where they disagree. EPS trajectory is upward: ₹0.28 → ₹0.46 → ₹0.66 → ₹0.84 in last 4 quarters. TTM PAT YoY +52% confirms EARNINGS DRIVEN cycle. Zero FII stake; promoter stable at 75%. Institutional signal neutral, small-cap BSE-listed stock with thin float. What is not proven yet. One hospital, one city, any adverse event (key doctor attrition, clinical incident, regulatory action) has no operational hedge. The test written in advance. Single-Asset Concentration Risk. Measured by: Single-Asset Concentration Risk Any regulatory notice, NABH suspension, or disclosure of key doctor departure by the next result. The test written in advance. Related-Party Governance (Parent Corporate Guarantee). Measured by: Related-Party Governance (Parent Corporate Guarantee) Any invocation of guarantee; parent group's credit metrics; dividend policy by the next result. The test written in advance. Occupancy Plateau Near Capacity Ceiling. Measured by: Occupancy Plateau Near Capacity Ceiling Occupancy trending above 87% with flat ARPOB, signals overcrowding not mix improvement by the next result. What the company does. Q3 FY26: revenue +33.7% YoY to ₹82 Cr, PAT +82.7% to ₹13.7 Cr, EBITDA margin expanded from 27.5% to 31.1%, cost operating leverage kicking in as Maa Kauvery fills up. Occupancy at 82% (vs 74% a year ago), IPD volumes +18% YoY, ARPOB at ₹31,481 (+17% YoY), pricing power intact in a Tier-II market with limited quality competition. 9-month FY26 PAT +89.9%, D/E improved to 0.38 from 0.50, cash ₹49 Cr vs ₹17.5 Cr a year ago, balance sheet improving as the new facility ramps. Next catalyst: further occupancy push toward 85%+ and a new hospital launch in FY27. Lever 1 · Operating leverage: building. 200-bed Mother & Child Care facility operational since Jan 2024, occupancy at 82% by Q3 FY26 drives incremental revenue at ~60% gross margin on fixed-cost base. What proves it keeps working: Maa Kauvery Ramp-Up (Operating Leverage). It stops working if Any regulatory notice, NABH suspension, or disclosure of key doctor departure. Lever 2 · Value-added mix: building. Blended ARPOB ₹31,481, up 17% YoY, driven by higher-complexity cases and ARPP IP at ₹1.22 lakh/case (+8% YoY). What proves it keeps working: ARPOB Expansion (Mix and Pricing). Lever 14 · A bigger market to serve: building. OPD volumes +32% YoY to 53,406 in Q3 FY26, outpatient channel feeding IPD pipeline and growing brand reach across 9 surrounding districts. What proves it keeps working: OPD Volume Growth (Catchment Expansion). Lever 15 · Market-share gains: building. Kauvery group credit upgrade to IND AA- (India Ratings, Dec 2024) and parent plan to add 1,000 beds by FY27 strengthen KMCSHIL's referral network and payer mix. What proves it keeps working: Group-Level Brand Tailwind. Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026. The story check is re-scored every results season; the record below never changes. ## What is KMC Speciality Hospitals (India) management's track record? Briefing regeneration post-bug-fix. ### Regulatory and governance record Cannot assess, briefing generation failed. (Checked 15 March 2026.) ## How much does KMC Speciality Hospitals (India) earn on its capital? KMC Speciality Hospitals (India) Ltd earned a ROCE of 26% in FY26. That is up from a low of 2% in FY14. Its return on capital used (ROIC) is 12.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 15.4% net margin and 0.92× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 15.4% net margin × 0.92× asset turnover × 1.58× leverage (assets divided by equity) ≈ 22.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 24.2% − 12.0% = +12.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 24.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 21.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does KMC Speciality Hospitals (India) have too much debt? KMC Speciality Hospitals (India) Ltd has total debt of ₹89.0 Cr against shareholder equity of ₹243 Cr as of Sep 2026, so its debt is 0.37× its equity. Year by year, that ratio went from 0.33 in FY22 to 0.40 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the KMC Speciality Hospitals (India) shareholding pattern? No group of KMC Speciality Hospitals (India) Ltd's owners changed its stake by a full percentage point over the last two years. Foreign institutions moved +0.0 points over the same period, to 0.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +0.0 points over 8 quarters, to 75.0%; Foreign institutions: +0.0 points over 8 quarters, to 0.0%. ## How far is KMC Speciality Hospitals (India) from balance-sheet trouble? For KMC Speciality Hospitals (India) Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does KMC Speciality Hospitals (India) rank in its industry? 74.5 out of 100, rank 1 of 20 in Hospitals, with 75% of the evidence available. KMC Speciality Hospitals (India) Ltd scores 74.5 out of 100 against the 20 companies it is compared with in Hospitals, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 31 + 22.6 + 8.4 + 12.5 = 74.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is KMC Speciality Hospitals (India) compared with? KMC Speciality Hospitals (India) ranks 1 of 20 Hospitals companies on the 4-Factor Sector Score, with 74.5 out of 100. 1. KMC Speciality Hospitals (India) Ltd this page KMCSHIL · breaking out · Most evidence points up · 75% evidence 74.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 32.2% · Profit 93.8% · Operating margin change 2 points · 100% evidence Capital efficiency 22.6/25 · ROCE 26.2% (year to Mar 2026) · Operating margin 30.1% · 100% evidence Valuation 8.4/20 · P/E 52.7× · PEG n/a · 50% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 46.9% · 1 year 154.7% · 25% evidence · 7 of 7 weeks ahead Exact sum: 31 + 22.6 + 8.4 + 12.5 = 74.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · leader · Most evidence points up · 90% evidence 69.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/35 · Revenue 16.7% · Profit 19.6% · Operating margin change 2 points · 100% evidence Capital efficiency 20.4/25 · ROCE 22.6% (year to Mar 2026) · Operating margin 29% · 100% evidence Valuation 9.2/20 · P/E 25.9× · PEG n/a · 50% evidence Relative strength 16.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 9% · Strength vs NIFTY 500 (same reading) 10.7% · 1 year 8.4% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.1 + 20.4 + 9.2 + 16.4 = 69.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · quiet · Most evidence points up · 100% evidence 67.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 19.4% · Profit 35.2% · Operating margin change 1 points · 100% evidence Capital efficiency 16.8/25 · ROCE 17.4% (year to Mar 2026) · Operating margin 15.6% · 100% evidence Valuation 11.9/20 · P/E 56.6× · PEG 2.19 · 100% evidence Relative strength 11.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 2.9% · 1 year 19.3% · 100% evidence · 2 of 12 weeks ahead Exact sum: 27.5 + 16.8 + 11.9 + 11.4 = 67.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Most evidence points up · 75% evidence 67.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 18.4% · Profit 18.2% · Operating margin change 1 points · 100% evidence Capital efficiency 20.5/25 · ROCE 19.9% (year to Mar 2026) · Operating margin 19.9% · 100% evidence Valuation 14.7/20 · P/E 21.2× · PEG n/a · 50% evidence Relative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -6.5% · 25% evidence · 3 of 12 weeks ahead Exact sum: 23.2 + 20.5 + 14.7 + 9.2 = 67.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 90% evidence 67.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.1/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.1/25 · ROCE 12.4% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 8.9/20 · P/E 52.4× · PEG n/a · 50% evidence Relative strength 15.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 42.7% · Strength vs NIFTY 500 (same reading) 42.7% · 1 year 171.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.1 + 11.1 + 8.9 + 15.2 = 67.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · turning · Most evidence points up · 100% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 26.2% · Profit 9.3% · Operating margin change 4 points · 100% evidence Capital efficiency 18.7/25 · ROCE 17.4% (year to Mar 2026) · Operating margin 25.2% · 100% evidence Valuation 9.1/20 · P/E 62.4× · PEG 2.39 · 100% evidence Relative strength 16.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.8% · Strength vs NIFTY 500 (same reading) 13.2% · 1 year 17.1% · 100% evidence · 6 of 12 weeks ahead Exact sum: 20.7 + 18.7 + 9.1 + 16.9 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · losing its lead · Evidence leans up · 100% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.3/25 · ROCE 14.6% (year to Mar 2026) · Operating margin 17.7% · 100% evidence Valuation 12.3/20 · P/E 47.4× · PEG 1.58 · 100% evidence Relative strength 15.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.8% · Strength vs NIFTY 500 (same reading) 13.2% · 1 year 23.4% · 100% evidence · 9 of 12 weeks ahead Exact sum: 20.9 + 12.3 + 12.3 + 15.4 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 82% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 50.4% · Profit 19.1% · Operating margin change 1 points · 95% evidence Capital efficiency 12.4/25 · ROCE 12.9% (year to Mar 2026) · Operating margin 23.7% · 76% evidence Valuation 6.7/20 · P/E 55.2× · PEG n/a · 50% evidence Relative strength 19.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 25.3% · Strength vs NIFTY 500 (same reading) 26.5% · 1 year 43.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 12.4 + 6.7 + 19.1 = 59.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · leader · Evidence leans up · 71% evidence 58.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.0/25 · ROCE 17.2% (year to Mar 2026) · Operating margin 30.1% · 100% evidence Valuation 10.0/20 · P/E 38.6× · PEG n/a · 50% evidence Relative strength 12.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 15.4% · 1 year 16% · 25% evidence · 9 of 12 weeks ahead Exact sum: 19.3 + 17 + 10 + 12 = 58.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 22.8% · Profit 16.8% · Operating margin change -2 points · 100% evidence Capital efficiency 19.7/25 · ROCE 17.4% (year to Mar 2026) · Operating margin 31% · 100% evidence Valuation 11.5/20 · P/E 43.7× · PEG 2.34 · 100% evidence Relative strength 3.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -8% · Strength vs NIFTY 500 (same reading) -6.7% · 1 year -5.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 19.7 + 11.5 + 3 = 51.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · turning · Evidence leans down · 78% evidence 49.0 out of 100 Growth Capital Valuation Relative 12. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans down · 75% evidence 47.9 out of 100 Growth Capital Valuation Relative 13. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · basing · Evidence leans down · 85% evidence 44.5 out of 100 Growth Capital Valuation Relative 14. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 100% evidence 42.4 out of 100 Growth Capital Valuation Relative 15. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 67% evidence 40.2 out of 100 Growth Capital Valuation Relative 16. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · quiet · Evidence leans down · 82% evidence 40.0 out of 100 Growth Capital Valuation Relative 17. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Evidence leans down · 100% evidence 35.8 out of 100 Growth Capital Valuation Relative 18. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 82% evidence 30.6 out of 100 Growth Capital Valuation Relative 19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 75% evidence 24.6 out of 100 Growth Capital Valuation Relative 20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 40% evidence 41.6 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to KMC Speciality Hospitals (India) in size? KMC Speciality Hospitals (India) is the 16th largest of 20 Hospitals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Kovai Medical Center & Hospital, Artemis Medicare Services and Indraprastha Medical Corporation. Just below it: Dr Agarwals Eye Hospital, Sakar Healthcare and Shalby. ### Hospitals companies close in size 1. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) ₹7,101 crore 2. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹5,436 crore 3. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) ₹3,282 crore 4. KMC Speciality Hospitals (India) Ltd ₹3,220 crore 5. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) ₹2,942 crore 6. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) ₹2,246 crore 7. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) ₹1,285 crore [All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies) ### Companies close in size in other industries 1. [Ashoka Buildcon Ltd](https://www.sectoralpha.in/stocks/ashoka-buildcon-ltd) ₹3,234 crore · Construction & Contracting 2. [Sanghvi Movers Ltd](https://www.sectoralpha.in/stocks/sanghvi-movers-ltd) ₹3,226 crore · Capital Goods - EPC/Cranes 3. KMC Speciality Hospitals (India) Ltd ₹3,220 crore 4. [Kiri Industries Ltd](https://www.sectoralpha.in/stocks/kiri-industries-ltd) ₹3,218 crore · Dyes & Pigments 5. [Bajaj Electricals Ltd](https://www.sectoralpha.in/stocks/bajaj-electricals-ltd) ₹3,210 crore · Domestic Appliances ## What else do people ask about KMC Speciality Hospitals (India)? ### What is KMC Speciality Hospitals (India)'s share price today? KMC Speciality Hospitals (India) Ltd's share price is ₹197.42, +154.7% over the past year. The whole company is worth ₹3,217 Cr on the market. It is at its highest price of the past 52 weeks (range ₹75 to ₹197), 58.4% above its 200-day average. The price has been rising for 52 weeks (as of 18 November 2026). ### What were KMC Speciality Hospitals (India)'s latest quarterly results? KMC Speciality Hospitals (India) Ltd reported revenue of ₹93.0 Cr and net profit of ₹16.0 Cr for the Sep 2026 quarter. Revenue rose 24.0% and profit rose 45.5% compared with a year earlier. Earnings per share were ₹0.99 (as of 18 November 2026). ### What is KMC Speciality Hospitals (India)'s market cap? KMC Speciality Hospitals (India) Ltd's market capitalisation is ₹3,217 Cr at a share price of ₹197.42. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is KMC Speciality Hospitals (India) performing? KMC Speciality Hospitals (India) Ltd's share price has been rising for 52 weeks. In its latest quarter, revenue rose 24.0% and profit rose 45.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 44 weeks running (as of 18 November 2026). ### Will KMC Speciality Hospitals (India)'s share price go up? This page does not forecast KMC Speciality Hospitals (India) Ltd's share price. What it shows instead: the share price is ₹197.42, and it has been rising for 52 weeks. Its P/E of 52.6× is higher than 87% of its own last 11 years (as of 18 November 2026). ### Who owns KMC Speciality Hospitals (India)? Promoters own 75.0% of KMC Speciality Hospitals (India) Ltd, foreign institutions 0.0%, domestic institutions, and the public 25.0% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026). ### Does KMC Speciality Hospitals (India) have too much debt? KMC Speciality Hospitals (India) Ltd has a moderate amount of debt: its debt is 0.40× its equity, and its operating profit is 10 times its interest bill. FY26 borrowings were ₹84.0 Cr against equity of ₹210 Cr. Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026). ### Where is KMC Speciality Hospitals (India) in its business cycle? KMC Speciality Hospitals (India) Ltd's FY26 operating margin was 28.8%, against a 13-year range of 6.3% to 28.8%. The latest quarter was 30.1%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the KMC Speciality Hospitals (India) story? The main question: the share price moved +154.7% in a year while yearly earnings per share moved +119.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is KMC Speciality Hospitals (India) a stock worth studying right now? What the numbers show: KMC Speciality Hospitals (India) Ltd's share price has risen faster than its earnings: +154.7% in a year, against +119.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india This is research, not advice. We’re not SEBI-registered.